

Closing share Price (02/11/2022)

EUR 68.50


Target valuation range

EUR 79.00 - 96.00

Risk	Low
Reuters	LUX.LU
Bloomberg	LXMP LX
Shares number (m)	20.15
Market cap. (m)	1,380
NAV 03/11/2022	104.10
(Discount)/Premium	-34.2%
1 year price perf.	-9.9%
Diff. with Euro Stoxx	7.7%
Volume (sh./day)	1,133
H/L 1 year	79.50 - 68.50
Free Float	24.2%
Foyer Finance	50.4%
Sofina Group	6.1%
Stable Shareholders	16.6%
Treasury Shares	2.7%

Company description

Luxempart is a Luxembourg based investment holding company with more than 25 years of existence. Luxempart invests in several European countries, mainly in the DACH region, Luxembourg, Belgium, France and Northern-Italy.



Analyst:

Joren Van Aken

Equity Analyst

+32 2 662 88 83

j.vanaken@degroofpetercam.com

Luxempart

(Partially) Exiting RIMED at nice IRR in dry market

This report is considered as a marketing communication. It has been commissioned and paid for by Luxempart and has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is also not subject to any prohibition on dealing ahead of the dissemination of investment research.

RIMED to partner up with Unilabs, Luxempart makes nice IRR

RIMED, a leading Swiss diagnostic radiology company, will partner up with Unilabs, a leading diagnostic services provider. In this partnership, Unilabs will take a majority stake in RIMED. During this transaction, Luxempart will reduce its stake in RIMED from 27.4% to 5.5%. As a result, Luxempart will generate an IRR significantly exceeding its long-term objectives (>15%).

Valuation unknown, but likely to be big (DPe EUR 70-75m)


Although we do not know exactly the value of RIMED in the portfolio, the company was one of the few Healthcare companies in the portfolio. As Luxempart does provide NAV per sector for direct investments, we can therefore derive a rough estimate of the valuation. We believe RIMED was in the NAV for about EUR 70-75m.

Impressive exit in a very dry market

We are positively surprised about this transaction. As we have seen in the market (e.g. Pitchbook Q3 VC report & PGIM - 'The New Dynamics of Private Markets'), liquidity is drying up. Typical exits from private companies like an IPO are very difficult in today's environment and if there are exits they are typically in the form of a downturn. A good example of that was Klarna, which had to raise funds in 2022 at a valuation which was 85% lower than its previous one in 2021. As a result, we see a lot of GPs creating continuation funds and passing old assets on to the new vintage without having to book an impairment. This also helps them to preserve their management and performance fees. Therefore, it is even more impressive that Luxempart was able to (partially) exit while still generating an IRR of >15% in the current market.

EUR	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
End FY Price	50.50	53.00	49.00	74.50	-	-	-
End FY NAV	70.09	78.40	85.11	107.80	-	-	-
End FY Discount	-27.9%	-32.4%	-42.4%	-30.9%	-	-	-
EPS	3.44	10.31	7.80	24.81	-	-	-
Cash EPS	-	-	-	-	-	-	-
Div.	1.41	1.48	1.60	1.80	1.94	2.10	2.27
Y/Y	5.0%	5.2%	8.1%	12.5%	8.0%	8.0%	8.0%
Payout	40.9%	14.4%	20.5%	-	-	-	-
Yield	2.9%	2.8%	3.3%	2.4%	2.8%	3.1%	3.3%

Exhibit 1 VC exit activity



Source: Pitchbook Q3 VC report

This sale will bring the net cash position to >EUR 400m again or >20% of NAV. In the current environment, a large cash position can be an opportunity to get into attractive businesses at good prices. In order to prevent this from becoming a reinvestment risk, it is key that the investment company has a clear cut strategy on how to deploy it. As a reminder, Luxempart's strategy consists of EUR 25-100m tickets in both listed and private companies. Although no sectors are excluded, the company does have an affinity with financial services & insurance, telecommunication, security, healthcare and industrials.

Another important factor is that Luxempart is a patient and long-term investor. The company has no strict deadline to exit within 3 years, as you would expect with typical PE players. Instead, Luxempart prefers to partner up with the management or founding families of the company and see how they can support them in the best way possible.

Be that either through buy & build, organic & geographical expansions or partnering up with fellow companies as we have seen today.

Valuation

We estimate today's NAV to be EUR 104.1 per share. That implies a discount of 34.2% which is both significantly above the historical average (~30%) and our target discount of 15%. After updating our model for lower equity markets since our last report (partially offset by today's sale), we slightly lower our valuation range to EUR 79-96 (vs. EUR 81-99 before).

Compared to the current share price, this range provides an upside of 15.3-40.2%. Considering this upside, we believe Luxempart remains an attractive investment for patient investors that can withstand the limited liquidity.

Exhibit 2 NAV at 03/11/2022

Participations	Spot value (€m)	Per share	% of GAV	12m Target
Direct Investment (Listed)	169.6	8.4	10%	178.1
Direct Investments (Private)	1,067.3	53.0	64%	1,195.4
of which Foyer (DPe)	514.6	25.5	31%	560.9
Investment Funds	427.3	21.2	26%	474.3
Gross Asset Value (GAV)	1,664.2	82.6	100%	1,847.8
Net cash	433.6	21.5		433.6
Net Asset Value (NAV)	2,097.8	104.1		2,281.4
per share	104.1			113.2
Share price	68.5			
	Current	Hist. average	Target	
Discount	-34%	-30%	-15%	
Target range in EUR		79	96	

Source: Degroof Petercam estimates

Commissioned Research

Degroof Petercam is commissioned by this company to publish research and is paid for this service.

Disclosures applicable when indicated on the front page

1. Degroof Petercam acts as a liquidity provider for this company and is paid for these services.
2. Degroof Petercam has provided corporate finance services in the past 12 months for this company.

General disclaimer

About Degroof Petercam

This report has been prepared by Bank Degroof Petercam SA/NV ("Degroof Petercam").

Degroof Petercam is a financial institution authorised by and under the prudential supervision of, as a credit institution, the National Bank of Belgium and under the supervision of the Financial Services and Markets Authority. It has its registered office at 44, rue de l'Industrie, 1040 Brussels and is registered with the crossroads bank for enterprises under number 0403.212.172.

No investment research

This report is considered as a marketing communication. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Not approved by the competent regulator

This report is not subject to any statutory prior approval requirement by a competent supervisory authority. As a result, this report has not been, and will not be submitted for approval to any competent supervisory authority.

Content of the report

This report has been prepared by the sell-side research team of Degroof Petercam. All opinions, views, estimates and projections included herein reflect the personal views of the author on the subject company and related securities as of the date of this report. This report does not necessarily reflect the views of Degroof Petercam as institution and is subject to change without notice. The analyst(s) claim(s) furthermore not to have any meaningful financial interest in any of the aforementioned companies, not to be conflicted and not to have accepted any inducement from any person with a material interest in the subject company of the report at hand. The remuneration of the analysts is subject to the remuneration policy of Degroof Petercam and can be consulted [here](#).

The information and opinions contained in this report have been compiled or arrived at from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness.

Validity of the report

Any information, opinion or estimate contained in the present report is, regardless of source, given in good faith and may only be valid as of the date on which this report is published and is subject to change. The value of any investment may also fluctuate as a result of market changes. Degroof Petercam is not obliged to inform the recipients of this report of any change to such opinions or estimates.

Not for retail clients

This report is meant exclusively for professional clients or eligible counterparties (as defined in the Markets in Financial Instruments Directive 2014/65/EU) and is not intended for retail clients use.

Review by the subject company of this report

Degroof Petercam reserves the right to submit a draft of the research report (excluding – where relevant - the target valuation range/fair value and the recommendation) for review to the subject company with the sole purpose of correcting any inadvertent material factual inaccuracies.

Conflict of interest

It should be noted that Degroof Petercam and the subject company have entered into an agreement relating to the production of this report. Degroof Petercam has received a remuneration from the subject company for the drafting and dissemination of this report.. This remuneration is (i) a fixed fee which has been agreed between the subject company and Degroof Petercam prior to the drafting and publication of this report and (ii) under no circumstances positively or negatively influenced by the content of this report.

Due to the broad activities of the group to which Degroof Petercam belongs, it may occur that Degroof Petercam or any of its affiliates:

- holds positions or effect transactions in the securities of the company mentioned herein or any member of its group;
- performs or seeks to perform investment banking services for such companies (such as corporate finance advice services);
- acts as a market maker or a liquidity provider for the securities of the company mentioned herein;
- performs any other services it is legally entitled to provide;
- hold a mandate in the subject company;
- hold a significant stake in the subject company.

In this regard, Degroof Petercam is required to have arrangements in place to identify, prevent and manage conflicts of interest between itself and clients and between different clients. Degroof Petercam operates in accordance with a conflicts of interest policy under which Degroof Petercam has identified those situations in which there may be a conflict of interest and, in each case, the steps taken to manage that conflict. Degroof Petercam has taken reasonable care to ensure that objectivity of this research report and the independence of the author are ensured and it has put in place several arrangements (such as internal policies and procedures) in order to manage potential conflicts of interests. Degroof Petercam has for example implemented

a remuneration policy, a personal account dealing procedure and several organizational measures such as Chinese Walls which are designated to prevent against the wrongful disclosure and use of confidential and sensitive information. Where the arrangements under our conflicts of interest policy are not sufficient to manage a particular conflict, Degroof Petercam will inform the relevant client of the nature of the conflict so that the client can make a well-informed decision. Next to the aforementioned arrangements, Degroof Petercam has also implemented the internal arrangements required by article 37(1) of the Commission Delegated Regulation 2017/565.

No offer

This report does not constitute and should not be construed as, an offer or solicitation for the sale, purchase or subscription of any financial instrument. Any offer or entry into any transaction requires Degroof Petercam's subsequent formal agreement which may be subject to internal approvals and execution of binding transaction documents.

No investment advice

The information contained in this report should not be regarded as personalized and should not be considered as a recommendation of investment advice. Recipients should not construe the content of this report as legal, tax, accounting or investment advice or personal recommendation. Accordingly Degroof Petercam is under no obligation to, and shall not, determine the suitability for the recipient of any potential transaction described herein. Recipients should seek advice to their advisors in order to determine the merits, terms, conditions and risks of any potential transaction that may be described herein.

Forward looking statements

This report may contain forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the actual results, condition, performance, prospects, growth or opportunities to differ materially from those expressed in, or suggested by, these forward-looking statements. Forward-looking statements are not guarantees of future performance and there is no guarantee that any of the estimates or projections will be achieved. Actual results may vary from the projections and such variation may be material.

Past & simulated past performance

Any past or simulated past performance including back-testing, modelling or scenario analysis contained herein is no indication as to future performance. No representation is made as to the accuracy of the assumptions made within, or completeness of, any modelling, scenario analysis or back-testing.

Valuation method

Our target valuation is generally based on a combination of valuation methods including DCF, SOTP, peer group comparison, historical ratio analysis and others. The outcome of these valuation methods is sensitive to both external factors (e.g. interest rates and market valuations) and assumptions we make (e.g. on sales growth, profitability, or valuation discounts). Be aware that even small changes in these elements can lead to large changes in target valuation. More information on the valuation method used for this company can be found in the reports published on <https://www.degroofpetercam.com/en-be/commissioned-research>

No liability

Degroof Petercam accepts no liability whatsoever for any direct or consequential loss or damage arising from any use of this report or its content. This report does not purport to give an exhaustive description of the financial instrument and of the issuer of the financial instrument it relates to. Although all reasonable care has been taken to ensure that the information in this report is accurate, neither Degroof Petercam, nor any of its affiliated companies, directors, advisors or employees can be held liable for any incorrect, incomplete or missing information, or for any direct or indirect damage, losses, costs, claims, liabilities or other expenses which would result from the use of, or reliance on, this report, except in case of willful misconduct or gross negligence. The information contained in this report has not been independently verified by any independent third party.

Distribution restriction

The present report is exclusively intended to professional clients and eligible counterparties, to the exclusion of retail clients. It may not be copied, reproduced, marketed or distributed in whole or in part for any purpose whatsoever without the prior written consent of Degroof Petercam.

The present report may not be taken or transmitted or distributed, directly or indirectly, outside of the EEA (but for the United Kingdom).

Report completion and updates

This report was first disseminated by Degroof Petercam on 3 November 2022 08:40 CET

Valuations are continuously reviewed by the analyst and will be updated and/or refreshed regularly. The rationale behind a change in target valuation will be explained in such a refresher/update.

An overview of the research published on this company can be found on our website: <https://www.degroofpetercam.com/en-be/commissioned-research>
This website will also give you access to all of the commissioned research reports that have been disseminated during the preceding 12-month period.

This report has not been reviewed by the company prior to publication.

The report has been reviewed by Laura Roba, Equity Analyst.

Degroof Petercam Global Markets

www.degroofpetercam.com

Nijverheidsstraat / Rue de l'Industrie 44 – 1040 Brussels

De Entrée 238 A 7th floor – 1101 EE Amsterdam

Benoît Mortelmans +32 2 662 82 93

Equity Research / Analysts

Fernand de Boer	Retail/Food & Beverages	+31 20 573 5417
Kris Kippers	Consumer Goods/Holdings	+32 2 287 9259
Frank Claassen	Industrials	+31 20 573 5409
Christophe Dombu Youta, PhD	Biotech/Healthcare	+32 2 287 9051
Vincent Koppmair	Real Estate	+32 2 287 9673
Inna Maslova	Real Estate	+32 2 662 8644
Laura Roba	ESG/Medtech	+32 2 287 9276
Michael Roeg	Technology	+31 20 573 5422
David Seynnaeve, PhD	Biotech/Healthcare	+32 2 287 9771
Joren Van Aken	Holdings/Misc.	+32 2 662 8883
Luuk van Beek	Energy/Engineering/Construction	+31 20 573 5471
Herman van der Loos, CFA	Real Estate	+32 2 662 8304
Christel De Clerck	Support & Editing	+32 2 662 8302

Corporate Brokerage & Syndication

Gert Potvlieghe		+32 2 662 8289
Raymond de Wolff		+31 20 573 5414
Tineke Hosselaer	Corporate access	+32 2 662 8290
Charlotte Mertens	Corporate access	+31 20 573 5416

Sales

Anthony della Faille	+32 2 662 8724
Laurent Pierret	+32 2 662 8654

Equity Sales

Simon Vlamincx	+32 2 662 8291
Damien Fontaine	+32 2 662 8287
Assia Adanouj	+32 2 662 8768
Piethain Leune	+31 20 573 5436
Jeroen Van Genuchten	+31 20 573 5428
Beatrice Leysens - Assistant	+32 2 662 8262

Sales Trading

Veronique De Schoemaecker	+32 2 662 8280
Pieter De Moerloose	+32 2 662 8870
Fabrice Faccenda	+32 2 662 8986
Frédéric Lebrun	+32 2 287 9190

Fixed Income Sales

An-Sofie Meirsschaut	+32 2 662 8665
Olivier Gigounon	+32 2 287 9184
Lieven Krikilion	+32 2 287 9559
Sandra Timmermans	+32 2 662 8852

Derivatives

Karim Marrakchi	+32 2 662 8940
Eric Debeaud	+32 2 287 9827
Thierry De Wispelaere	+32 2 662 8674